PDF(Pubmed)
Abstract：
UNASSIGNED: Endoscopic endonasal surgery is effective in the treatment of sinonasal cancers. However, in cases of well-differentiated locally advanced neoplasms as well as recurrences, the most appropriate treatment is debated. The purpose of this study is to report a mono-institutional experience on craniofacial surgery performed in a tertiary-care referral centre.
UNASSIGNED: This was a retrospective analysis of 90 patients treated with transcranial and/or transfacial resection for sinonasal cancer between 2010 and 2020. Outcome measures included overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS) and recurrence-free survival (RFS).
UNASSIGNED: The 5-year OS, DSS and DFS were 48.2%, 60.6% and 28.7%, respectively. Factors correlated with prognosis were pT-classification (p = 0.002), histotype (p = 0.012) and dural involvement (p = 0.004). Independent prognostic factors were orbital apex infiltration (p = 0.03), age (p = 0.002) and adjuvant therapy (p = 0.03).
UNASSIGNED: When endoscopic endonasal surgery is contraindicated and chemoradiotherapy is not appropriate, craniofacial and transfacial approaches still represent an option to consider, despite the non-negligible morbidity.
UNASSIGNED: This was a retrospective analysis of 90 patients treated with transcranial and/or transfacial resection for sinonasal cancer between 2010 and 2020. Outcome measures included overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS) and recurrence-free survival (RFS).
UNASSIGNED: The 5-year OS, DSS and DFS were 48.2%, 60.6% and 28.7%, respectively. Factors correlated with prognosis were pT-classification (p = 0.002), histotype (p = 0.012) and dural involvement (p = 0.004). Independent prognostic factors were orbital apex infiltration (p = 0.03), age (p = 0.002) and adjuvant therapy (p = 0.03).
UNASSIGNED: When endoscopic endonasal surgery is contraindicated and chemoradiotherapy is not appropriate, craniofacial and transfacial approaches still represent an option to consider, despite the non-negligible morbidity.
摘要：
■鼻内镜手术治疗鼻窦肿瘤是有效的。然而,在分化良好的局部晚期肿瘤以及复发的情况下，最合适的治疗方法是有争议的。这项研究的目的是报告在三级护理转诊中心进行的颅面手术的单一机构经验。
■这是对2010年至2020年间经颅和/或经面部切除治疗鼻窦癌的90例患者的回顾性分析。预后指标包括总生存率（OS），疾病特异性生存率（DSS），无病生存期（DFS）和无复发生存期（RFS）。
■5年操作系统，DSS和DFS分别为48.2％，60.6%和28.7%，分别。与预后相关的因素是pT分类（p=0.002），组织型（p=0.012）和硬脑膜受累（p=0.004）。独立的预后因素是眶尖浸润（p=0.03），年龄（p=0.002）和辅助治疗（p=0.03）。
■当内镜鼻内手术禁忌且放化疗不合适时，颅面和经面部方法仍然是一个需要考虑的选择，尽管发病率不可忽视。
■这是对2010年至2020年间经颅和/或经面部切除治疗鼻窦癌的90例患者的回顾性分析。预后指标包括总生存率（OS），疾病特异性生存率（DSS），无病生存期（DFS）和无复发生存期（RFS）。
■5年操作系统，DSS和DFS分别为48.2％，60.6%和28.7%，分别。与预后相关的因素是pT分类（p=0.002），组织型（p=0.012）和硬脑膜受累（p=0.004）。独立的预后因素是眶尖浸润（p=0.03），年龄（p=0.002）和辅助治疗（p=0.03）。
■当内镜鼻内手术禁忌且放化疗不合适时，颅面和经面部方法仍然是一个需要考虑的选择，尽管发病率不可忽视。
